PAA — Pharmaust Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousMicro CapMomentum Trap
- AU$28.49m
- AU$26.84m
- AU$3.90m
- 26
- 14
- 67
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.33 | ||
| Price to Tang. Book | 36.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.31 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -128.16% | ||
| Return on Equity | -105.88% | ||
| Operating Margin | -157.16% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 4.36 | 4.12 | 3.67 | 4.51 | 3.9 | n/a | n/a | 3.42% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PharmAust Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing therapeutics for cancer, neurodegenerative diseases and viral infections in humans and cancer for animals. The Company's lead candidate, Monepantel (MPL), a potent and safe inhibitor of the mTOR pathway, a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase I clinical trials in humans and Phase II clinical trials in dogs. It has also initiated a preclinical program to screen its portfolio of aminoacetonitrile (AAD) compounds for anticancer activity. The Company's wholly owned subsidiary, Epichem Pty Ltd, continues to advance its disruptive waste conversion and re-purposing technology, Oxidative Hydrothermal Dissolution (OHD).
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- June 30th, 2023
- Incorporated
- August 3rd, 2000
- Public Since
- October 5th, 2001
- No. of Shareholders
- 3,060
- No. of Employees
- 52
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 347,474,940
- Address
- 5/3 Brodie Hall Drive,, Bentley, NEDLANDS, 6102
- Web
- https://www.pharmaust.com/
- Phone
- +61 892026814
- Auditors
- RSM Australia Partners
Upcoming Events for PAA
Similar to PAA
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Auscann group
Australian Stock Exchange - SEATS
Biome Australia
Australian Stock Exchange - SEATS
FAQ
What is the Pharmaust share price?
As of Today at 18:17 UTC, shares in Pharmaust are trading at AU$0.08. This share price information is delayed by 15 minutes.
How has the Pharmaust share price performed this year?
Shares in Pharmaust last closed at AU$0.08 and the price had moved by +15.49% over the past 365 days. In terms of relative price strength the Pharmaust share price has outperformed the ASX All Ordinaries Index by +18.65% over the past year.
What are the analyst and broker recommendations for Pharmaust?
There is no consensus recommendation for this security.
What is the Pharmaust dividend yield?
Pharmaust does not currently pay a dividend.
Does Pharmaust pay a dividend?
Pharmaust does not currently pay a dividend.
When does Pharmaust next pay dividends?
Pharmaust does not currently pay a dividend.
How do I buy Pharmaust shares?
To buy shares in Pharmaust you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pharmaust?
As of the previous close price of AU$0.08, shares in Pharmaust had a market capitalisation of AU$28.49m.
Where are Pharmaust shares listed?
Here are the trading details for Pharmaust:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: PAA
What kind of share is Pharmaust?
Based on an overall assessment of its quality, value and momentum Pharmaust is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pharmaust share price forecast for 2023?
We could not find analyst target price data for this security.
What is the trend in the Pharmaust share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmaust. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +13.28%.
As of the last closing price of AU$0.08, shares in Pharmaust were trading +0.39% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pharmaust PE Ratio?
The Pharmaust PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pharmaust?
Pharmaust's management team is headed by:
- Martine Keenan - CEO
- Robert Bishop - EDR
- John Horton - OTH
- Colette Sims - OTH
- Sam Wright - SEC
- Neville Bassett - NED